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Abstract  
The belief that G protein-coupled receptors exist and function as monomeric, non-interacting 
species has been largely supplanted in recent years by evidence, derived from a range of 
approaches, that indicate they can form dimers and/or higher-order oligomeric complexes. 
Key roles for receptor homo-dimerisation include effective quality control of protein folding 
prior to plasma membrane delivery and interactions with hetero-trimeric G proteins. Growing 
evidence has also indicated the potential for many co-expressed G protein-coupled receptors 
to form hetero-dimers/oligomers. The relevance of this to physiology and function is only 
beginning to be unravelled but may offer great potential for more selective therapeutic 
intervention.  
Introduction  
Protein-protein interactions are integral to the organisational structure and function of cell 
signalling networks, and many classes of receptors and other signal transducing polypeptides 
form constitutive or regulated dimers and/or higher order oligomers [1]. In recent years a vast 
range of studies have demonstrated the capacity of a large number of G protein-coupled 
receptors (GPCRs) to interact to form homo-dimers/oligomers. Such interactions are 
important for cell surface delivery, and the organisational structure of these complexes may 
also be central to the mechanisms of G protein binding and activation. More recently the 
potential for hetero-dimeric/oligomeric interactions between co-expressed GPCRs has also 
been explored extensively and such interactions can result in alterations in ligand 
pharmacology, the nature of the signal(s) generated and cellular trafficking of the complexes. 
Although a rapidly developing area, key questions relating to the general importance of 
GPCR hetero-dimerisation/oligomerisation in native tissues remain to be addressed 
adequately, largely because of the paucity of selective pharmacological tools and 
immunological reagents to identify and modulate the function of such hetero-dimers. 
Identification, generation and use of such reagents will be fundamental in defining if such 
complexes may be novel targets that can be exploited for therapeutic intervention.  
A large number of recent reviews [2- 9] have considered many of these topics. The current 
review will hence focus on the structural organisation of GPCR dimers/oligomers and the 
implications of this for function.  
The structural organisation of rhodopsin  
Only for the photon receptor rhodopsin are high resolution, 3 dimensional crystal structures 
available [10, 11]. However, these static structures of detergent-extracted receptor, although 
remarkably informative on the orientation and organisation of the seven transmembrane helix 
bundle, provided no insights into potential quaternary structure. By contrast, both the 
application of atomic force microscopy to discs from mouse rod outer segments [12] and the 
use of cryo-electron microscopy on 2-dimensional crystals of squid rhodospin [13] have 
shown higher-order organisation of the proteins. In the pictures obtained by atomic force 
microscopy, rhodopsin is organized within para-crystalline arrays with densely packed, 
double rows of the receptor. Using such images as a starting point, and given the high density 
of rhodopsin in rod outer segments, models of potential quaternary structure were generated 
that optimised packing arrangements. These models have suggested interactions between 
rows of dimers to be provided by contacts between elements of transmembrane domain I, 
whilst key interactions between monomers of a dimer are provided by contacts involving 
transmembrane domains IV and V [3, 14]. Interestingly, the electron density maps derived 
from the 2-dimensional crystals of squid rhodopsin provide evidence of a symmetrical 
transmembrane domain IV-transmembrane domain IV interaction as a key structural interface 
[13] and although squid rhodopsin has relatively low overall sequence identity with 
mammalian opsins this may well represent a conserved element in interactions between 
rhodopsin-like, family A GPCRs. As an alternative approach, Kota et al., [15] expressed 
opsin heterologously in COS1 cells. Following initial fluorescence resonance energy transfer 
(FRET) experiments to confirm interactions between forms of opsin tagged with either cyan 
or yellow fluorescent protein, dimer formation was assessed by the rate of disulphide bond 
formation in the presence of cupric orthophenanthroline, using opsin mutants in which a 
range of specific amino acids were mutated to cysteine. These studies showed most rapid 
dimer formation with the mutants W175C (transmembrane domain IV) and Y206C 
(transmembrane domain V) [15] consistent with key roles of these regions in quaternary 
structure.  
The structural organisation of other class A GPCRs  
High level expression of rhodopsin in rod outer segments has resulted in the capacity to 
purify substantial amounts of this receptor and to apply biophysical approaches to understand 
its organisation and function that have not generally been practical for other GPCRs. 
However, significant progress has recently been made in understanding the structural 
organisation of a number of other GPCRs (Table 1). The dopamine D2 receptor is a case in 
point. Employing cysteine cross-linking studies and forms of the D2 receptor in which amino 
acids of transmembrane domain IV that point away from the ligand binding pocket, defined 
as the water accessible core within the transmembrane helices, were mutated, Guo et al., [16] 
were initially able to demonstrate cross-linking of a D2 receptor containing Cys at position 
168 near the top of transmembrane domain IV (4.58 in the Ballesteros and Weinstein [17] 
numbering system). Such cross-linking did not occur when this residue was mutated. Guo et 
al., [18] followed up this initial study with a more comprehensive cross-linking scan over 23 
amino acids of transmembrane domain IV. Cross-linking interactions were shown to occur 
when cysteine residues were placed along two contiguous faces of this helix and the rate of 
cross-linking of residues in these faces was differentially altered in the presence of agonist 
and inverse agonist ligands, consistent with the concept that alterations at the homo-dimer 
interface might be important in the generation of active and inactive states of this receptor. 
Interestingly, cross-linking via amino acids 4.50, 4.54, and the previously studied 4.58, 
resulted in constitutive capacity of the receptor to promote [35S]GTPγS binding, suggesting 
that effective alignment of this interface between pairs of D2 receptors might be an important 
task for ligands that display agonism [18]. Earlier studies [19] examining interactions 
between fragments of the D2 receptor had also provided evidence for dimerisation involving 
transmembrane domain IV based, in part, on self-association of fragments of the receptor 
containing this element. Interestingly, however, the studies of Lee et al., [19] suggested that 
the transmembrane domain IV interface might only be one element responsible for 
dimeric/oligomeric organisation of the D2 receptor and Guo et al., [18] have suggested a 
transmembrane domain IV `promoter exchange' model for receptor activation that would 
require the organisational structure being at least a tetramer, if not a yet more complex 
structure.  
Evidence for a role of transmembrane domain IV as a dimer interface, and of higher order 
organisation, is not restricted to the D2 receptor. Carrillo et al., [20] indicated a key role for 
transmembrane domain IV in the a1b-adrenoceptor based on symmetrical interactions between 
receptor fragments containing this sequence. Furthermore, as similar studies also indicated a 
symmetrical interface to be provided by transmembrane domain I, Carrillo et al., [20] 
proposed a `daisy chain' organisation that could generate rows of monomers. Non-
symmetrical interactions involving transmembrane domains I and/or II with transmembrane 
domains V and/or VI, or conceivably elements of intracellular loop I that connects 
transmembrane domains I and II with intracellular loop III, that connects transmembrane 
domains V and VI, were then suggested to align the `rows of monomers'. The cysteine cross-
linking approach has also been used to suggest roles for elements of transmembrane helices I 
and II or IV in the quaternary structure of the complement C5a receptor [21]. Here again, the 
data were most easy to interpret as allowing oligomeric organisation rather than interactions 
being restricted to dimers. Although transmembrane domain IV has been a focus of attention 
in the studies noted above, a variety of other elements of the primary sequences of rhodopsin-
like GPCRs have been suggested to be important in generating quaternary interactions. These 
include contributions of sialylation and N-glycosylation at the extracellular face of the 
bradykinin B2 receptor [22], potentially of transmembrane domain V in the adenosine A2a 
receptor [23], transmembrane domain I and the N-terminal domain of the yeast a factor 
receptor [24-25] and transmembrane domain VI of the b2-adrenoceptor [26]. As well as direct 
experimental studies a range of computational approaches have also been applied to attempt 
to predict potential dimerisation interfaces within the helical bundles of rhodopsin-like 
GPCRs [27-31]. These have provided information that is, in general, in relatively good 
agreement with experimental observations. However, whether this is because of, or in spite 
of, the limited experimental data set is unclear. One extremely interesting and provocative 
prediction from the analyses of both Nemoto and Toh [29] and Filizola and Weinstein [30] is 
that the homo-dimerisation interfaces of even closely related GPCRs that respond to similar 
ligands may be markedly distinct. If this is confirmed by direct experiments it will provide 
interesting challenges in prediction and determination of hetero-dimer interfaces but may 
suggest means to selectively target and disrupt GPCR homo- and hetero-dimers, and hence 
may perhaps have therapeutic implications. To date, however, there have been no detailed 
experimental studies to define the molecular basis of hetero-dimeric interactions. 
Furthermore, some analyses suggest the potential for functionally important residues on the 
external face of each transmembrane helix of a GPCR [31], potentially consistent with the 
organisation of GPCRs into larger multimeric complexes. Each of the above noted 
computational studies focused on the formation of `contact' dimers. Earlier computational 
analyses had suggested the potential for the existence of so called `domain-swap' dimers [32], 
in which elements of each protomer were interchanged within the dimer. Although there is 
currently little experimental support for domain-swap dimers being commonplace, in the case 
of the histamine H1 receptor Bakker et al., [33] have provided evidence that such forms do 
exist. Defined point mutations in either transmembrane helix III (Asp107Ala) or 
transmembrane helix VI (Phe432Ala) eliminate binding of the antagonist [3H] mepyramine. 
However, [3H]mepyramine binding sites with the expected pharmacology of the histamine 
H1 receptor were generated when the Asp107Ala and Phe432Ala mutants were co-expressed. 
Although the number of [3H]mepyramine binding sites generated via this approach were low 
compared to when the wild type receptor was expressed, such results are consistent with the 
potential for contact dimers and domain-swap dimers to both form and co-exist [33].  
Formation of dimers/oligomers is an early step in GPCR maturation and cell surface 
delivery  
A substantial literature has provided evidence for GPCR dimerisation occurring at the level 
of synthesis in the endoplasmic reticulum or during protein maturation in the Golgi apparatus 
[9] (Table 2). Introduction of endoplasmic reticulum retention motifs into GPCRs not only 
result in lack of cell surface delivery of the modified receptor but can also hinder cell surface 
delivery of a co-expressed, unmodified receptor. Replacement of the C-terminal tail of the b2-
adrenoceptor with the equivalent region of the GABAb-R1 subunit, which contains a well 
characterised arginine-based endoplasmic reticulum retention signal, resulted in the modified 
b2-adrenoceptor being trapped in the endoplasmic reticulum of transfected cells [34]. This 
construct also limited cell surface delivery of co-expressed wild type b2-adrenoceptor [34]. 
As cell surface delivery of wild type b2-adrenoceptor was not compromised by co-expression 
of the wild type GABAb-R1, that is also retained in the endoplasmic reticulum but does not 
interact with the b2-adrenoceptor [34], such studies are indicative of protein-protein 
interactions between the two forms of the b2-adrenoceptor with the mutant acting as a 
dominant negative. The C-terminal 14 amino acids of the a2C-adrenoceptor also contain an 
endoplasmic reticulum retention motif. Addition of this sequence to the C-terminal tail of the 
chemokine CXCR1 receptor produced a form of this GPCR that was entirely limited to the 
endoplasmic reticulum [35]. Co-expression of the intracellularly-retained form of CXCR1 
with wild type forms of either CXCR1 or the closely related GPCR CXCR2 resulted in 
marked reduction in their cell surface delivery [35], whereas cell surface delivery of the a1A-
adrenoceptor, which was shown by a range of approaches to be unable to interact with 
CXCR1 with high affinity, was unaffected [35].  
As well as introduction of endoplasmic reticulum retention motifs into GPCRs lacking such 
sequences, mutations in a variety of positions can eliminate or limit cell surface trafficking of 
a receptor and the mutants may act as dominant negatives for cell surface delivery of wild 
type receptors. Such a strategy has recently been employed to examine interactions amongst 
a2-adrenoceptor subtypes [36] and a regulated secretion/aggregation technology was 
employed by Hansen et al., [37] to explore aspects of dimerisation and function of the 
angiotensin II AT1 receptor. An F(6X)LL motif, common in the proximal C-terminal tail of a 
number of rhodopsin-like GPCRs, has been suggested to be key in regulating endoplasmic 
reticulum to cell surface delivery [36]. However, as this region is the central core of the 
region often described as the `4th intracellular loop' or `helix 8', based on similarity of 
sequence with the equivalent region of bovine rhodopsin, it is likely that mutation in this 
region will have global effects on receptor folding and function and that it is not simply a 
motif that is key to release from the endoplasmic reticulum.  
Naturally occurring mutations in GPCRs are also known to limit GPCR cell surface delivery. 
For example, various mutations in the thyroid stimulating hormone receptor are known to 
result in aberrant cell surface expression and can exert dominant negative effects on cell 
surface delivery of the wild type receptor by forming a complex at the level of the 
endoplasmic reticulum [38]. This can potentially explain abnormal endocrine phenotypes in 
patients who are heterozygous for the mutation [38]. Similar molecular interactions appear to 
underlie effects of a mutant of the Frizzled 4 seven transmembrane domain receptor that is 
associated with familial exudative vitreoretinopathy [39], where co-expression with wild type 
Frizzled 4 shows that the mutant form dimerizes with wild-type Fz4, retains it in the 
endoplasmic reticulum and inhibits its signalling [39]. Equivalent observations have been 
made for a series of other receptors, including the calcium-sensing receptor [40] and the 
melacortin-1 receptor [41], where interactions between wild type and dominant negative 
mutants of the receptor may contribute to hair colour [41-42]. This general concept has 
recently developed into a specific sub-area of GPCR homo-dimerisation studies with both 
substantial support via basic studies, and with clear implications for disease [43-44]. A 
number of, but not all, endoplasmic reticulum-retained GPCR mutants can be `rescued' by 
treatment of cells expressing these mutants with so-called chemical or pharmacological 
chaperones [45-47], and there are potential therapeutic implications of this general approach 
that stretch well beyond diseases associated with endoplasmic reticulum-retained GPCR 
mutants [47]. To date, studies on endoplasmic reticulum retention of GPCRs and disease 
have been limited to homo-dimeric interactions. However, given the level of interest in 
GPCR hetero-dimeric interactions (see later) it would not be surprising if a mutant GPCR that 
is retained in the endoplasmic reticulum might limit cell surface delivery of a second co-
expressed wild type GPCR and limit its function.  
Although clearly vital, GPCR homo-dimerisation is not simply a strategy to ensure proper 
folding, maturation and cell surface delivery of GPCRs. Although even for rhodopsin, 
isolated monomers can be shown to be functional [48], monomers appear to have lower 
signal generation capacity than dimers/oligomers [49]. Based on the molecular dimensions of 
rhodopsin and its associated G protein transducin, models in which a rhodopsin dimer 
straddle or provide an appropriate footprint to bind a single transducin a,b/γ subunit hetero-
trimer effectively have been proposed [3, 14]. This would appear to provide an attractive 
model for efficient signal transduction requiring receptor dimerisation (Table 2), or indeed, 
higher order oligomerisation, to provide effective signal amplification via a relay system 
because measurements of the number of transducins that can be activated by a single photon 
of light [50] appear difficult to comprehend within a simple 1:1 organisation of rhodopsin 
dimer and transducin hetero-trimer. Indeed, early studies did suggest the potential of 
oligomeric organisation of G proteins in brain membranes [51-52]. Recent biophysical 
studies on recombinantly expressed receptors reconstituted with purified G proteins have also 
supported the idea of the basic unit of signal transduction of the BLT1 leukotriene B4 
receptor as a pentamer containing two receptors and the three subunits of a G protein hetero-
trimer [53]. Although less direct, studies on the 5-HT2C receptor [54], the a1b-adrenoceptor 
[55] and the DOP opioid receptor [56] are each consistent with this model.  
Theoretically, mutations or small molecules that prevent dimerisation might be expected to 
limit GPCR-mediated signal transduction. However, such effects may be difficult to separate 
from unfolding and incomplete receptor maturation. Equally, if dimerisation interfaces are 
quite extensive then minor mutation might be insufficient to ablate protein-protein 
interactions. Reported mutations that apparently eliminate protein-protein interactions for 
certain chemokine receptors do not limit cell surface delivery [57] and this appears 
inconsistent with the simple models delineated above. Also difficult to incorporate into a 
`one-size fits all' model of dimerisation/oligomerisation in the endoplasmic reticulum/Golgi 
being vital for cell surface delivery are reports of agonist ligands either promoting, or being 
required for, GPCR dimerisation [58-59]. In studies that rely exclusively on resonance energy 
transfer techniques [60-61] relatively small alterations in receptor conformation may alter the 
observed signal and be interpreted as a agonist-induced alteration in dimeric/oligomeric 
status. However, if increases or decreases in signal are produced by both agonists and 
antagonist ligands this may suggest that the effect measured is not related to alterations in 
overall quaternary structure [62-63]. A series of other studies have indicated the potential for 
agonist ligands to cause dissociation of certain pre-formed GPCR dimers/oligomers [64-65]. 
Although subject to the same caveats as increases of resonance energy transfer signal, it is 
unclear if, or how, dissociated dimers would re-associate during the processes of receptor 
internalisation and recycling to the cell surface as there is evidence for the internalisation of 
receptor-homo-dimers in response to binding of agonist ligands [66].  
Although there have been suggestions that GPCR dimerisation/oligomerisation might be 
promoted at relatively high receptor expression levels and hence potentially be at least 
partially an artefact of over-expression, studies on the extent of b-adrenoceptor dimerisation 
have indicated that this is unaltered over a wide range of expression levels [67] whilst CCR5 
receptor dimerisation/oligomerisation occurs at relatively low, physiologically relevant, 
levels of expression [68]. Although many GPCRs are indeed expressed in relatively low 
levels, in many cases the heterogeneity of physiological tissue used to measure expression 
levels probably results in a marked under-estimate of expression levels in individual cells that 
actually express the GPCR of interest and hence true measures of the level of expression of 
various GPCRs in, for example, specific neurones remain undefined. Furthermore, although 
data indicate that GPCRs such as the neurokinin NK1 receptor exist as monomers [69] this is 
not generally consistent with evidence that information transfer reflecting ligand binding to 
one protomer may be communicated to the G protein by altering the orientation of the dimer 
interface and transfer of information via the partner protomer [18].  
GPCR hetero-dimerisation/oligomerisation  
Given the extensive literature on the existence and relevance of GPCR homo-
dimers/oligomers and the importance of GPCRs as the targets of small molecule therapeutics 
it is hardly surprising that the potential existence and relevance of GPCR hetero-
dimers/oligomers has been actively studied. With more than 400 genes encoding non-sensory 
GPCRs in the human [70] and other mammalian genomes co-expression of a number of these 
in individual cells is to be expected. Efforts to assess the relative interaction affinities of 
closely related GPCRs to form hetero-dimers/oligomers versus homo-dimers/oligomers have 
been based largely on `saturation' resonance energy transfer experiments [60]. Such studies 
have indicated that, for example, the b1-adrenoceptor and b2-adrenoceptors [67], the CXCR1 
and CXCR2 chemokine receptors [35], DOP, KOP and MOP opioid receptors [71] and 
various subtypes of muscarinic acetylcholine receptors [72] generate hetero-dimers with 
similar, or only slightly lower, affinity that the corresponding homo-dimers. For each of the 
examples noted above there is clear evidence of the co-expression of the GPCR pairs in 
native cells and, as such, unless there are temporal or other means to limit the co-translation 
of mRNA into protein it is likely that these hetero-dimers/oligomers are indeed generated in 
native tissues. Although it has been suggested that opioid receptor hetero-dimers might only 
form following cell surface delivery, and in a G protein-dependent manner [73], other studies 
of these receptors [71] have supported the general model of dimer/oligomer formation 
occurring during receptor synthesis and maturation. Early studies on the relative interaction 
affinity of GPCRs to generate homo- versus hetero-interactions [74] concluded that hetero-
oligomers between closely related GPCRs subtypes would form more efficiently than 
between less closely related GPCRs. Whilst intellectually appealing, particularly if the basic 
dimer/oligomer interface(s) is the same for different class A GPCRs, computational 
modelling studies that favour different interfaces even for homo-dimers of closely related 
receptors [30] suggest that such a simple view requires rigorous analysis across a wide range 
of receptors. Indeed, there are examples in which the relative propensity of two receptors to 
form the hetero-dimer appears to be greater than for the corresponding homo-dimers [75].  
Functional consequences of hetero-dimerisation  
In recent years a very large number of studies [see 2, 4-7, 9 for review] have attempted to 
explore functional sequelae of GPCR hetero-dimerisation. In many cases such studies have 
employed pairs of GPCRs that are likely to be co-expressed in physiological settings, but in a 
number of published studies this does not appear to have been a priority in the experimental 
design. Prior to considering some of the observations reported, and the implications thereof, it 
is important to remember that not all cases in which co-expression of two GPCRs modulates 
the function of one or both are likely to reflect or require hetero-dimerisation. For example, 
heterologous desensitisation can profoundly alter receptor function.  
Despite such caveats, effects of hetero-dimerisation on signal identity, ligand pharmacology 
and receptor trafficking have all been described. One issue is that unless the hetero-dimer 
forms much more efficiently that the corresponding homo-dimers, co-expression of two 
GPCRs must be anticipated to result in the presence of both homo-dimers and hetero-dimers 
and, although some suggestions have been examined, strategies to resolve signals produced 
by homo- and hetero-dimers in the same cells are generally limited [2]. Despite these issues, 
a number of clear differences in the function and pharmacology of co-expressed pairs of 
GPCRs have been reported and attributed to the generation of GPCR hetero-dimer/oligomer 
complexes. Again, however, it is important to discriminate effects that reflect direct protein-
protein interactions rather than indirect effects produced via downstream signalling and 
feedback control.  
GPCR hetero-dimerisation and signal generation  
As noted earlier, current views on the physical organisation of GPCRs and associated 
G proteins favour a model in which a GPCR dimer provides a footprint suitable to bind a 
single G protein a,b,γ hetero-trimer [3, 53-54]. A GPCR hetero-dimer could then offer a 
docking interface with differing G protein selectivity than the corresponding GPCR homo-
dimers (Table 2). A range of studies has reported data that are at least consistent with such a 
model. Although both MOP and DOP receptors are generally considered highly selective for 
activation of pertussis toxin-sensitive hetero-trimeric G proteins, when co-expressed, George 
et al., [76] have reported that signals insensitive to pertussis toxin treatment were generated. 
Interestingly, this has been demonstrated to reflect a switch in coupling such that Gz becomes 
activated by opioid agonists [77] and that the distal C-terminal tail of each receptor plays a 
role in this switch [77]. In a similar vein, co-stimulation of co-expressed dopamine D1 and 
D2 receptors, which a range of approaches have confirmed to have the ability to form hetero-
dimers [78], results in generation of a phospholipase C-mediated Ca2+ signal [79], although 
the D1 receptor is usually associated with stimulation, and the D2 receptor with inhibition, of 
adenylyl cyclase. Perhaps even more interesting in relation to drug discovery is that co-
expression of pairs of GPCRs can alter the potency and/or ability of receptor agonists to 
generate signals. For example, co-expression of the orexin-1 receptor with the cannabinoid 
CB1 receptor has been reported to enhance the potency of the peptide orexin-A to stimulate 
phosphorylation of the ERK1 and 2 MAP kinases 100 fold, an effect that was blocked by the 
CB1 receptor antagonist/inverse agonist rimonabant [80]. The concept that hetero-
interactions between GPCRs might alter the potency of action of natural agonists and that this 
may be modulated by synthetic ligands that have no direct affinity for that GPCR when tested 
in isolation but may affect a hetero-dimer/oligomer containing the receptor is clearly of great 
interest and, if widely applicable, will require reconsideration of ligand screening approaches 
[2]. An interesting extension to this has recently been reported for interactions between the 
MT1 melatonin receptor and the orphan receptor GPR50 [81]. When co-expressed, the 
presence of GPR50 is reported to abolish the binding of melatonin to the MT1 receptor and a 
key contribution to this effect is provided by the long intracellular tail of GPR50. Most 
interestingly, both GPR50 and the MT1 receptor are expressed endogenously in hCMEC/D3 
endothelial cerebral cells. siRNA-mediated knock-down of GPR50 levels increased levels of 
[125I]melatonin binding [81], consistent with the concept that GPR50/MT1 hetero-
dimerisation prevents binding of the ligand. This is not the only example in which a currently 
orphan GPCR is able to modulate the function or potency of a ligand at a second co-
expressed receptor. The mas-related gene (Mrg) receptors are largely if not exclusively 
expressed in sensory dorsal root ganglia. Milasta et al. [82] employed cells in which the 
orphan GPCR MrgE was expressed constitutively whilst the related GPCR MrgD, that is 
known to be activated by b-alanine, was expressed from a single, defined inducible locus in a 
time- and inducer-concentration-dependent manner. As anticipated, MrgE-MrgD hetero-
dimers/oligomers were only produced subsequent to induction of MrgD expression and the 
amount of hetero-dimer present reflected the level of MrgD expression. Functional potency 
of b-alanine was enhanced by the presence of MrgE, potentially because the hetero-dimer 
was maintained at the cell surface rather than becoming internalized in response to the MrgD 
agonist [82]. Of equal interest is the concept that a hetero-dimer comprising two co-expressed 
GPCRs may share a common ligand. As well as the Mrg receptors (which are also called 
sensory neuron-specific G protein-coupled receptors (SNSRs) in some studies), dorsal root 
ganglia express the DOP opioid receptor. Bovine adrenal-medulla-peptide-22 is reported to 
be an agonist at both the DOP receptor and the sensory neuron-specific G protein-coupled 
receptor-4 (SNSR-4) but the relevant pharmacophores are distinct. When the two GPCRs 
were co-expressed in HEK293 cells bovine adrenal-medulla-peptide-22-mediated inhibition 
of adenylyl cyclase (the DOP receptor signal) was lost whilst stimulation of phospholipase C 
(the SNSR-4 signal) was retained [83]. Furthermore, co-addition of selective DOP and 
SNSR-4 agonists promoted SNSR-4 but not DOP signalling, indicating that in the 
DOP/SNSR-4 hetero-dimer, DOP receptor ligand binding and/or function may be masked. 
Although indirect, the size of bovine adrenal-medulla-peptide-22 may allow this ligand to 
bind to both elements of the hetero-dimer concurrently and there is evidence that synthetic, 
designed bivalent ligands that incorporate distinct pharmacophores at either end of the 
molecule may be able to modulate the function of hetero-dimers of opioid receptor subtypes 
[84-85]. Significant efforts in medicinal chemistry are now targeting the concept of 
generating molecules that may allow study of GPCR dimers [86]. In a similar fashion, hetero-
dimerisation between somatostatin sst2a and somatostatin sst3 receptors has been reported to 
eliminate binding of a somatostatin sst3 receptor selective agonist [87].  
One of the issues frequently raised in relation to efforts to study the pharmacology 
and function of GPCR hetero-dimers is that either transient or stable expression of two 
GPCRs is likely to result in the production of homo-dimers as well as potential hetero-
dimers. One approach to address this issue for closely related GPCRs that display similar 
affinity to generate homo- and hetero-interactions is to express one of the pair to substantially 
higher levels than the other. It would then be reasonable to assume that the bulk of the less 
highly expressed GPCR would be present within hetero-dimers [88]. Assuming ligands with 
good affinity and high selectivity for the less highly expressed GPCR are available, 
comparisons of their affinity, function and structure-activity relationships in cells co-
expressing the two GPCRs with those that express this receptor alone and at similar total 
levels may offer insights. As a variant of this, the expression of one of the potential partners 
can be controlled via an inducible promoter to regulate the extent of hetero-dimerization. 
Milasta et al. [82] employed this strategy to explore interactions between the Mrg D and 
MrgE and this approach is likely to become much more widely employed. A rather unusual 
approach to ensure production only of GPCR `hetero-dimers' is to express both from a single 
open reading frame [89]. Given the 7 transmembrane domain organisation of GPCRs, this 
required insertion of an extra transmembrane domain between transmembrane helix VII of 
the first receptor and transmembrane helix I of the second. The results obtained with a 
construct in which the adenosine A2A receptor and the long isoform of the dopamine D2 
receptor were linked together in this way are rather difficult to interpret, not least because the 
measures of ligand binding capacity of the two elements were very different. However, 
although other studies in which hetero-dimerisation has been reported to alter the 
characteristics of ligand binding have focused on agonists [81, 90-91], and where the effect 
may be related to alterations in G protein coupling, it is at least conceptually possible that 
antagonist binding capacity and/or affinity might also be modulated by hetero-dimerisation.  
GPCR hetero-dimers as physiologically relevant molecular species  
Studies on GPCR hetero-dimerisation performed in transfected cell lines require 
support from physiological systems before becoming real therapeutic targets (Table 2). The 
opioid receptors have contributed significantly to the development of thinking in this area and 
it has been suggested than DOP-MOP hetero-dimers may be of particular relevance in 
improving morphine-based analgesia by limiting tolerance and dependence [92-94]. Equally, 
the recent claim that 6'-guanidinonaltrindole is both a spinally selective analgesic and a DOP-
KOP hetero-dimer selective agonist [95] has provided support for the physiological 
expression of opioid receptor hetero-dimers.  
The physiological function of receptors for angiotensin II also appears to be controlled via 
hetero-dimerisation. Interaction partners have included the bradykinin B2 receptor and the 
mas proto-oncogene [96-100]. Abidar et al., [101] have recently employed confocal 
fluorescence resonance energy transfer to indicate that the angiotensin II AT2 receptor and 
bradykinin B2 receptor are in close proximity in PC12W cell membranes and have suggested 
that influencing their dimerisation, might offer a potential therapeutic strategy for the 
treatment of hypertension and other cardiovascular and renal disorders. Equally, interactions 
between the angiotensin II AT1 receptor and the bradykinin B2 receptor have been reported in 
renal mesangial cells isolated from spontaneously hypertensive rats and in higher levels 
compared with cells from normotensive controls [97]. These authors also suggest that this 
hetero-dimer may contribute to angiotensin II hyper-responsiveness of mesangial cells in 
experimental hypertension [97]. It has also been suggested that levels of this hetero-dimer are 
increased in pre-eclampsia [98-99] and display increased sensitivity toward angiotensin II. 
Alteration of function associated with receptor hetero-dimerisation can also be productively 
studied in knock-out animals. Elimination of the Mas proto-oncogene results in enhanced 
contraction of mesenteric microvessels to angiotensin II but not to endothelin [100]. This is 
consistent with an observed Mas-AT1 receptor hetero-dimer interaction limiting the function 
and/or binding of angiotensin II. However, as noted earlier, hetero-dimerisation may not be 
the only contributing factor to such an effect. The Mas proto-oncogene displays high levels of 
agonist-independent, constitutive activity [101] and activation of protein kinase C via such 
constitutive activity can desensitise the AT1 receptor. Thus, reduced desensitisation of the 
AT1 receptor in the absence of Mas is also consistent with the enhanced function of 
angiotensin II, without a need to invoke hetero-dimerisation as a regulatory mechanism.  
Increasing evidence is also beginning to provide evidence that GPCR hetero-dimerisation 
may be relevant to airway function and sensitivity and to inflammatory responses. McGraw et 
al., [102] have recently provided evidence for the presence of an EP1 prostanoid receptor/b2-
adrenoceptor hetero-dimer in which the b2-adrenoceptor is poorly coupled to elevation of 
cAMP levels and hence to bronchial relaxation. The authors suggest that such a mechanism 
may contribute to beta-agonist resistance found in asthma [102]. Similarly, interactions 
between the chemokine CXCR1 receptor and a number of GPCRs that respond to 
lysophosphatidic acid or sphingosine 1-phosphate have been observed [103] and variation in 
expression levels of these receptors in individuals may be relevant to the extent of interleukin 
8-mediated white cell chemotaxis.  
The other key area of relevance of class A GPCR hetero-dimerization for in vivo function has 
developed from long term understanding of the interplay between receptors for adenosine and 
dopamine. A substantial literature, covering basic biochemical studies to more clinically 
relevant systems has been produced and reviewed [104-107]. Furthermore, hetero-dimeric 
interactions between the adenosine A1 and A2A receptors have recently been reported to play 
a key role in pre-synaptic control of striatal glutamatergic neurotransmission [108]. Equally, 
although more direct experiments on their existence and relevance in the CNS need to be 
performed, interactions between the cannabinoid CB1 receptor and both the D2 dopamine 
receptor [109] and the MOP opioid receptor [110] are certainly of great interest and may be 
of physiological relevance, particularly as CB1 receptor knock-out animals display reduced 
ethanol-induced conditioned place preference and increased levels of striatal dopamine D2 
receptors [111], whilst D2 dopamine receptors modulate the G protein coupling profile of the 
cannabinoid CB1 receptor [112]. Although it is clearly far more challenging to confirm 
GPCR hetero-interactions in physiologically relevant cells and tissues, detailed analysis of 
the function and pharmacology of GPCRs in cells and tissues of `knock-out' animals, and 
particularly conditional knock-outs, as well as the reconstitution of function and 
pharmacology by introduction of potential hetero-dimer/oligomer pairs into cells from knock-
out animals [113] is likely to provide useful information.  
Modulating GPCR hetero-dimer function  
Both to understand the functional significance of GPCR hetero-dimers in vivo and to 
explore their potential as selective therapeutic targets requires the identification of hetero-
dimer selective ligands or the development of strategies that can selectively disrupt hetero-
dimer pairs. As noted earlier, there is a significant, long standing literature on this concept of 
synthesising hetero-dimer selective ligands, not least in relation to the medicinal chemistry of 
opioid receptor ligands. Indeed, a recent study on molecules in which distinct KOP and DOP 
pharmacophores were linked via spacer arms have indicated certain of these molecules to 
display substantially higher affinity in cells co-expressing the two GPCRs than in mixtures of 
cells expressing each individually [84]. Molecules of this nature are unlikely to represent a 
starting point for molecules that can be employed therapeutically but may be very useful tools 
to aid understanding. It was thus a considerable surprise when 6'-guanidinonaltrindole, a 
relative simply analogue of a well known KOP receptor ligand, was recently described as a 
DOP-KOP hetero-dimer selective agonist [95]. Furthermore, its efficacy as a spinally-
selective analgesic resulted in the conclusion that DOP-KOP hetero-dimers may be expressed 
in spinal cord but not in brain [95]. There is no doubt that this publication has both raised 
awareness of the therapeutic potential of targeting GPCR hetero-dimers [114] and raised 
expectation that a range of such ligands will be identified via appropriate screening strategies. 
Other ligands certainly show indications of GPCR hetero-dimer selectivity. For example, 
although studied in a somewhat artificial manner, a number of anti-parkinsonian compounds 
appear to have high agonist affinity at the dopamine D2/D3 receptor hetero-dimer [115]. It is 
certainly possible that many ligands, including those studied previously, will unexpectedly 
show either substantial hetero-dimer selectivity or will modulate hetero-dimer function in 
animal studies and clinical settings despite never have been screened for such effects. Of 
course, strategies other than the use of conventional small molecule antagonists may 
potentially be useful to disrupt both GPCR homo- and hetero-dimers/oligomers and hence 
limit function. In one of the earliest detailed studies of GPCR homo-dimerization, a peptide 
corresponding to transmembrane domain VI of the b2-adrenoceptor was shown to disrupt 
both protein-protein interactions and signal generation [116]. Equally, although the 
mechanism is entirely unclear, infusion of peptides corresponding to transmembrane domain 
VII of a number of GPCRs into animals has been reported to interfere selectively with GPCR 
function [117]. Pepducins are cell penetrating peptides incorporating sequences from GPCRs 
and have been shown to have potential as therapeutic agents [118-119]. Although the 
targeting of protein-protein interaction interfaces has attracted limited interest in the drug 
discovery industry, if it emerges that GPCR homo-dimers and hetero-dimers interact via 
different sequence elements, then such an approach may certainly be worthy of consideration. 
The protease activated receptors, PAR1 and PAR4 associate as a hetero-dimeric complex in 
human platelets and a combination of small-molecule antagonists and pepducins has recently 
been described as being effective in treating carotid artery occlusion [120]. Further studies in 
this area are likely to also contribute to a greater understanding of the existence and relevance 
of GPCR hetero-dimers in the selective regulation of physiological processes. Given the 
importance of GPCRs as therapeutic targets [121] this may offer a means for enhanced 
selectivity in the use of GPCR ligands as medicines.  
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Tables  
Table 1. Structural domains reported to be involved in GPCR 
dimerisation/oligomerisation  
Receptor  Implicated domains  References  
Rhodopsin  TMD IV (V)  3, 14 (15)  
Dopamine D2  TMD IV  18, 19  
±1b-adrenoceptor  TMD IV(I,V/VI)  20  
Complement C5a  TMD I,II,IV  21  
Bradykinin B2  ECD  22  
Adenosine A2a  TMD V  23  
Yeast ± factor  TMD I, ECD  24, 25  
²2-adrenoceptor  TMD VI  26  
TMD = transmembrane domain. ECD = extracellular domain  
Table 2 Proposed roles of GPCR dimerisation/oligomerisation  
Role of 
dimerisation/oligomerisation  Receptor(s)  Refs.  
Protein folding  ²2-adrenoceptor  34  
 CXCR1  35  
 ±2-adrenoceptors 36  
 TSH receptor  38  
 Frizzled 4  39  
 
Calcium 
sensing 
receptor  
40  
 Melacortin-1 receptor  41  
 
CXCR1-
CXCR2  
hetero-dimer  
35  
Efficient signal transduction  Rhodopsin  3, 14  
 
BLT1 
leukotriene 
B4 receptor  
53  
G-protein selectivity (hetero-
dimers)  
MOP and 
DOP 
receptors  
76, 
77  
 
D1 and D2 
dopamine 
receptors  
78, 
79  
Signal Alteration/ Modulation 
(hetero-dimers)  
Orexin-1 
receptor and 
cannabinoid 
CB1  
80  
 
Melatonin 
MT1 and 
GPR50  
81  
 MrgD and MrgE  82  
 DOP receptor and SNSR-4  83  
 Somatostatin sst2a and sst3 87  
 
Control of physiological 
function  
(heterodimers)  
DOP and 
KOP 
receptors  
95  
 Angiotensin 
AT1 and 
Bradykinin 
B2  
97, 
98, 
99  
 Angiotensin AT1 and Mas  
100, 
101  
 
EP1 
prostanoid 
receptor and 
²2-
adrenoceptor  
102  
 
Various 
adenosine 
and 
dopamine 
receptors  
104-
107  
 Adenosine A1 and A2A  
108  
 
 
Dopamine 
D2 and 
cannabinoid 
CB1 ?  
110  
 
41  
 
